Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BMEA

BMEA - Biomea Fusion, Inc. Stock Price, Fair Value and News

$1.26-0.04 (-3.08%)
Market Closed

19/100

BMEA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

19/100

BMEA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.07

Target 3M

$1.21

Target 6M

$1.14

BMEA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMEA Price Action

Last 7 days

-10.6%

Last 30 days

4.1%

Last 90 days

-5.3%

Trailing 12 Months

-70.5%

BMEA RSI Chart

BMEA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BMEA Valuation

Market Cap

89.1M

Price/Earnings (Trailing)

-0.93

Price/Sales (Trailing)

23.5

Price/Free Cashflow

-1.03

BMEA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.07

Target 3M

$1.21

Target 6M

$1.14

BMEA Fundamentals

BMEA Revenue

Revenue (TTM)

4.2M

Rev. Growth (Yr)

-66.95%

Rev. Growth (Qtr)

-30.57%

BMEA Earnings

Earnings (TTM)

-95.7M

Earnings Growth (Yr)

49.96%

Earnings Growth (Qtr)

20.89%

BMEA Profitability

Return on Equity

-612.79%

Return on Assets

-173.43%

Free Cashflow Yield

-97.11%

BMEA Investor Care

Shares Dilution (1Y)

95.11%

Diluted EPS (TTM)

-2.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202504.2M00
20249.9M8.8M7.3M5.6M
20232.8M5.3M7.4M8.9M
2022129.0K309.0K871.0K1.8M
202126.7K50.3K74.0K100.0K
20200003.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Biomea Fusion, Inc.

BMEA
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
 CEO
 WEBSITEhttps://biomeafusion.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES94

Biomea Fusion, Inc. Frequently Asked Questions

BMEA is the stock ticker symbol of Biomea Fusion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Biomea Fusion, Inc. is 89.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BMEA's fair value in chart for subscribers.

The fair value guage provides a quick view whether BMEA is over valued or under valued. Whether Biomea Fusion, Inc. is cheap or expensive depends on the assumptions which impact Biomea Fusion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BMEA.

As of Wed Jan 28 2026, BMEA's PE ratio (Price to Earnings) is -0.93 and Price to Sales (PS) ratio is 23.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BMEA PE ratio will change depending on the future growth rate expectations of investors.